Information Provided By:
Fly News Breaks for June 14, 2019
REGN
Jun 14, 2019 | 09:45 EDT
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals following updated Phase 1 results for REGN1979, a CD20xCD3 bispecific antibody, in B-cell non-Hodgkin lymphoma. The data "continues to impress," with 93% over response rate and 71% complete response in follicular lymphoma, Raymond tells investors in a research note. The analyst continue to see REGN1979 as an "up and coming value driver" and he keeps an Overweight rating on Regeneron with a $435 price target.
News For REGN From the Last 2 Days
There are no results for your query REGN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.